Moreover, given the concomitant stimulatory effect on both muscle mass and insulin sensitivity, the administration of short‐acting beta2‐agonists during periods of limb immobilisation or bed rest is a highly promising approach to attenuate or even prevent muscle disuse‐induced atrophy and insulin resistance (Dirks et al., 2020). Here, INS is linked to Insulin resistance.